AbbVie Secures EU Approval for SKYRIZI in Children, Targeting New Frontier

NORTH CHICAGO, IL – June 23, 2026 – In a move that reinforces its dominance in the immunology sector, AbbVie has secured European Commission (EC) approval for its blockbuster drug SKYRIZI® (risankizumab) to treat moderate to severe plaque psoriasis in children and adolescents aged six and older. This landmark approval not only opens a new therapeutic avenue for a vulnerable and underserved patient population but also represents a significant strategic expansion for one of AbbVie's key growth drivers, promising to extend its market leadership for years to come.

The approval introduces a novel 55 mg pre-filled syringe, specifically designed to support weight-based dosing for younger patients weighing less than 40 kg. For executive investors, this development is a clear signal of AbbVie's adeptness at maximizing the lifecycle of its key assets while addressing critical unmet medical needs.

A Breakthrough for an Underserved Population

Psoriasis is not just an adult disease. Nearly a third of all cases begin before the age of 18, casting a long shadow over the formative years of many children. The physical burden of painful, itchy lesions is often compounded by a significant psychosocial toll. When lesions appear on visible areas like the face and scalp, children face an increased risk of social stigma, school absenteeism, and the development of comorbidities like anxiety and depression.

Despite this profound impact, the treatment landscape for pediatric psoriasis has been notoriously lacking. Research shows that a staggering 70% of pediatric patients rely solely on topical therapies, which are often insufficient for moderate to severe cases. While some older systemic drugs and biologics are available, their use can be limited by concerns over long-term safety, cumbersome administration, or a lack of specific approval for younger age groups. This has created a major treatment gap, leaving many children and their families struggling to manage the chronic condition effectively.

SKYRIZI’s approval directly addresses this gap. As a targeted interleukin-23 (IL-23) inhibitor, it works by selectively blocking a key cytokine involved in the inflammatory process of psoriasis. This precision offers a more advanced approach than broader immunosuppressants. The EC's decision was underpinned by robust data from the Phase 3 OptIMMize-1 and OptIMMize-2 clinical trials, which demonstrated significant improvements in skin clearance and quality of life. Critically, the safety profile in the 137 pediatric patients studied was consistent with the well-established profile in adults, with no new safety signals emerging.

"Particularly for pediatric psoriasis patients, early diagnosis and management can prevent symptoms from worsening and improve quality of life in the long-term," said Dr. Nina Magnolo, a lead investigator of the OptIMMize-1 study. "The EC's approval of risankizumab provides younger patients with more options including weight-based dosing and allows physicians to address unmet clinical needs of children living with moderate to severe psoriasis with confidence."

Fortifying AbbVie’s Immunology Empire

From an investor's perspective, this pediatric label expansion is a masterstroke in strategic asset management. SKYRIZI is a cornerstone of AbbVie's post-Humira growth strategy, and its performance has been nothing short of spectacular. With global revenues hitting $4.5 billion in the first quarter of 2026 alone and a full-year projection of $21.6 billion, the drug is a commercial juggernaut. This new indication is set to fuel that engine further.

The global pediatric psoriasis market, valued at nearly $15 billion in 2024, is projected to swell to over $47 billion by 2034. By securing an indication for children as young as six, AbbVie is positioning SKYRIZI to capture a significant share of this growing market. It enters a competitive but evolving field that includes other biologics like Novartis's Cosentyx (secukinumab) and Eli Lilly's Taltz (ixekizumab). However, SKYRIZI's strong efficacy data, favorable dosing schedule, and now a specific, weight-based option for young children give it a distinct competitive edge.

"Today's approval of SKYRIZI for pediatric psoriasis patients is a meaningful step forward for millions worldwide who are looking for additional treatment options to better manage this chronic disease in their formative years," stated Dr. Roopal Thakkar, AbbVie's chief scientific officer. This statement underscores the company's dual focus: addressing patient needs while simultaneously executing a well-defined commercial strategy. By expanding SKYRIZI's label, AbbVie not only builds a competitive moat around its immunology franchise but also secures a vital revenue stream that will contribute to growth for the next decade.

The Path to Patients: Navigating Europe's Complex Market

While the EC's pan-European approval is a critical milestone, it is the first step in a complex journey to patient access. The real test now begins as AbbVie navigates the intricate web of individual national reimbursement systems across the continent. Gaining market access in Europe is not a monolithic process; it requires separate negotiations and evaluations in each country.

Health Technology Assessment (HTA) bodies, such as Germany's Institute for Quality and Efficiency in Health Care (IQWiG), France's Haute Autorité de Santé (HAS), and the UK's National Institute for Health and Care Excellence (NICE), will now conduct their own rigorous reviews. These agencies will scrutinize SKYRIZI's clinical data, comparative effectiveness against existing therapies, and its cost-effectiveness to determine whether it should be funded by national health systems. This process can be lengthy and challenging, with payers demanding substantial evidence of value to justify the price of a premium biologic.

Investors should therefore temper short-term expectations, as it will take time for this new indication to translate into meaningful sales across Europe. AbbVie’s success will hinge on its ability to effectively communicate the drug's value proposition—not just in terms of skin clearance, but also its long-term impact on quality of life and the potential to reduce the overall healthcare burden associated with poorly controlled pediatric psoriasis.

The Long View on Safety and Sustained Value

For any chronic therapy initiated in childhood, the long-term safety profile is paramount. Physicians and parents will rightly demand robust, long-term data before widely adopting a new systemic treatment. AbbVie is addressing this through the OptIMMize-2 open-label extension study, which will continue to track the safety and efficacy of SKYRIZI in pediatric patients over an extended period. The drug's favorable multi-year safety record in adults provides a strong foundation of confidence, but ongoing pediatric-specific data will be crucial for building trust and driving uptake.

A strong long-term safety profile is also a key strategic asset. It de-risks the brand, protects its market share from future competitors, and solidifies its status as a potential standard of care. By investing in this long-term evidence generation, AbbVie is not only fulfilling its regulatory and ethical obligations but is also ensuring the durability of its franchise. For children suffering from the debilitating effects of psoriasis, the approval of an effective, targeted therapy like SKYRIZI offers the promise of not just clearer skin, but a better, more confident childhood and adolescence.